Free Trial

4basebio (4BB) Competitors

4basebio logo
GBX 1,173 -12.00 (-1.01%)
(As of 12/20/2024 09:57 AM ET)

4BB vs. SLN, OXB, PRTC, HZD, VRP, ARIX, BVXP, FARN, AVCT, and CIR

Should you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.

4basebio vs.

Silence Therapeutics (LON:SLN) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.

Silence Therapeutics' return on equity of 0.00% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
4basebio N/A -231.29%-54.30%

In the previous week, Silence Therapeutics and Silence Therapeutics both had 1 articles in the media. Silence Therapeutics' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
4basebio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Silence Therapeutics received 203 more outperform votes than 4basebio when rated by MarketBeat users.

CompanyUnderperformOutperform
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%
4basebioN/AN/A

2.0% of 4basebio shares are owned by institutional investors. 68.4% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Silence Therapeutics has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
4basebio£311K483.16-£9.84M-£0.78-1,503.85

Summary

Silence Therapeutics beats 4basebio on 5 of the 8 factors compared between the two stocks.

Get 4basebio News Delivered to You Automatically

Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

4BB vs. The Competition

Metric4basebioBiotechnology IndustryMedical SectorLON Exchange
Market Cap£150.26M£165.68M£5.14B£1.89B
Dividend YieldN/A3.64%5.09%5.46%
P/E Ratio-1,503.85115.5190.131,843.16
Price / Sales483.1618,531.021,117.09389,641.00
Price / Cash16.0812.8743.1028.69
Price / Book-28.618.594.782.78
Net Income-£9.84M-£20.67M£120.31M£155.66M
7 Day Performance-1.01%-1.05%-1.92%-2.01%
1 Month Performance-9.77%174.77%13.65%21.46%
1 Year Performance72.50%134.18%28.34%29.47%

4basebio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
4BB
4basebio
N/AGBX 1,173
-1.0%
N/A+68.1%£150.26M£311,000.00-1,503.85101Positive News
SLN
Silence Therapeutics
N/AGBX 535
-0.9%
N/AN/A£480.35M£11.35M-11.01100News Coverage
Positive News
High Trading Volume
OXB
Oxford Biomedica
N/AGBX 423.50
flat
GBX 433.33
+2.3%
+116.5%£446.20M£97.28M-295.83891Gap Down
PRTC
PureTech Health
2.2489 of 5 stars
GBX 170
+4.4%
GBX 455
+167.6%
+2.5%£407.01M£3.33M-745.89300News Coverage
High Trading Volume
HZD
Horizon Discovery Group plc (HZD.L)
N/AGBX 184.50
flat
N/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822News Coverage
Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 3,480.21
+0.7%
N/A-23.7%£181.67M£13.60M2,135.1012
FARN
Faron Pharmaceuticals Oy
N/AN/AN/A-45.8%£175.45M£-725,000.00-524.0634
AVCT
Avacta Group
N/AGBX 46.25
+6.5%
N/A-57.2%£165.71M£22.62M-513.33120News Coverage
Negative News
CIR
Circassia Group
N/AGBX 34
-6.8%
N/AN/A£142.66M£27.90M3,400.00111News Coverage
Gap Down

Related Companies and Tools


This page (LON:4BB) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners